{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,2]],"date-time":"2026-08-02T15:45:54Z","timestamp":1785685554409,"version":"3.56.0"},"reference-count":10,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2018,6,26]],"date-time":"2018-06-26T00:00:00Z","timestamp":1529971200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"},{"start":{"date-parts":[[2018,6,26]],"date-time":"2018-06-26T00:00:00Z","timestamp":1529971200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Br J Dermatol"],"published-print":{"date-parts":[[2018,9]]},"DOI":"10.1111\/bjd.16607","type":"journal-article","created":{"date-parts":[[2018,3,31]],"date-time":"2018-03-31T10:46:10Z","timestamp":1522493170000},"page":"747-749","source":"Crossref","is-referenced-by-count":27,"title":["Effective anti-programmed death-1 therapy in a<i>SUFU<\/i>-mutated patient with Gorlin-Goltz syndrome"],"prefix":"10.1093","volume":"179","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5244-9286","authenticated-orcid":false,"given":"A.","family":"Moreira","sequence":"first","affiliation":[{"name":"Department of Dermatology; Universit\u00e4tsklinikum Erlangen; Friedrich-Alexander-University Erlangen-Nuremberg (FAU); 91054 Erlangen Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.C.","family":"Kirchberger","sequence":"additional","affiliation":[{"name":"Department of Dermatology; Universit\u00e4tsklinikum Erlangen; Friedrich-Alexander-University Erlangen-Nuremberg (FAU); 91054 Erlangen Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Toussaint","sequence":"additional","affiliation":[{"name":"Department of Dermatology; Universit\u00e4tsklinikum Erlangen; Friedrich-Alexander-University Erlangen-Nuremberg (FAU); 91054 Erlangen Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Erdmann","sequence":"additional","affiliation":[{"name":"Department of Dermatology; Universit\u00e4tsklinikum Erlangen; Friedrich-Alexander-University Erlangen-Nuremberg (FAU); 91054 Erlangen Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Schuler","sequence":"additional","affiliation":[{"name":"Department of Dermatology; Universit\u00e4tsklinikum Erlangen; Friedrich-Alexander-University Erlangen-Nuremberg (FAU); 91054 Erlangen Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Heinzerling","sequence":"additional","affiliation":[{"name":"Department of Dermatology; Universit\u00e4tsklinikum Erlangen; Friedrich-Alexander-University Erlangen-Nuremberg (FAU); 91054 Erlangen Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2018,6,26]]},"reference":[{"key":"10.1111\/bjd.16607-BIB0001|bjd16607-cit-0001","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1136\/adc.66.10_Spec_No.1162","article-title":"Family implications of neonatal Gorlin's syndrome","volume":"66","author":"Evans","year":"1991","journal-title":"Arch Dis Child"},{"key":"10.1111\/bjd.16607-BIB0002|bjd16607-cit-0002","doi-asserted-by":"crossref","first-page":"4155","DOI":"10.1200\/JCO.2014.58.2569","article-title":"Germline mutations in SUFU cause Gorlin syndrome-associated childhood medulloblastoma and redefine the risk associated with PTCH1 mutations","volume":"32","author":"Smith","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1111\/bjd.16607-BIB0003|bjd16607-cit-0003","doi-asserted-by":"crossref","DOI":"10.1007\/s10689-018-0073-7","article-title":"Mutations in SUFU and PTCH1 genes may cause different cutaneous cancer predisposition syndromes: similar, but not the same","author":"Huq","year":"2018","journal-title":"Fam Cancer"},{"key":"10.1111\/bjd.16607-BIB0004|bjd16607-cit-0004","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1200\/JCO.2013.49.9525","article-title":"Open-label, exploratory phase II trial of oral itraconazole for the treatment of basal cell carcinoma","volume":"32","author":"Kim","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1111\/bjd.16607-BIB0005|bjd16607-cit-0005","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1001\/jamadermatol.2015.1187","article-title":"Incidence estimate of nonmelanoma skin cancer (keratinocyte carcinomas) in the U.S. population, 2012","volume":"151","author":"Rogers","year":"2015","journal-title":"JAMA Dermatol"},{"key":"10.1111\/bjd.16607-BIB0006|bjd16607-cit-0006","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1056\/NEJMoa1113713","article-title":"Efficacy and safety of vismodegib in advanced basal-cell carcinoma","volume":"366","author":"Sekulic","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1111\/bjd.16607-BIB0007|bjd16607-cit-0007","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1002\/cncr.26374","article-title":"Randomized controlled trial of acitretin versus placebo in patients at high-risk for basal cell or squamous cell carcinoma of the skin (North Central Cancer Treatment Group study 969251)","volume":"118","author":"Kadakia","year":"2012","journal-title":"Cancer"},{"key":"10.1111\/bjd.16607-BIB0008|bjd16607-cit-0008","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1634\/theoncologist.2016-0496","article-title":"FDA approval summary: pembrolizumab for the treatment of recurrent or metastatic head and neck squamous cell carcinoma with disease progression on or after platinum-containing chemotherapy","volume":"22","author":"Larkins","year":"2017","journal-title":"Oncologist"},{"key":"10.1111\/bjd.16607-BIB0009|bjd16607-cit-0009","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1684\/ejd.2017.3209","article-title":"Nivolumab for recurrent cutaneous squamous cell carcinoma: three cases","volume":"28","author":"Blum","year":"2018","journal-title":"Eur J Dermatol"},{"key":"10.1111\/bjd.16607-BIB0010|bjd16607-cit-0010","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s40425-017-0228-3","article-title":"Basal cell carcinoma: PD-L1\/PD-1 checkpoint expression and tumor regression after PD-1 blockade","volume":"5","author":"Lipson","year":"2017","journal-title":"J Immunother Cancer"}],"container-title":["British Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbjd.16607","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/bjd.16607\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,2]],"date-time":"2024-07-02T13:42:11Z","timestamp":1719927731000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bjd\/article\/179\/3\/747\/6732468"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6,26]]},"references-count":10,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,9]]}},"URL":"https:\/\/doi.org\/10.1111\/bjd.16607","archive":["Portico"],"relation":{},"ISSN":["0007-0963"],"issn-type":[{"value":"0007-0963","type":"print"}],"subject":[],"published":{"date-parts":[[2018,6,26]]}}}